In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% ...

Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive ...

Another common feature: Patients with a number of autoimmune diseases, especially women, often suffer heart attacks and ...

IAVI reports its single-dose Lassa fever vaccine is safe and effective, paving way for advanced trials across West Africa.

Volunteers were monitored for 12 months post-vaccination, with immune responses activating both humoral and cellular immunity ...

It's one of medicine's biggest mysteries — why sometimes our immune system attacks our own bodies. Autoimmune diseases affect ...

Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases ...

Our latest Focus Issue looks at what we’ve learnt over the past decade and what’s next for the field of trained immunity.

Nicole Charky-Chami is a senior editor based in Los Angeles, writing and producing breaking news. She teaches journalism courses for UCLA Extension and previously taught at Loyola Marymount University ...

Convicted sex trafficker Ghislaine Maxwell wants immunity and an advance look at the questions if Congress expects her to publicly testify about her ex-boyfriend, Jeffrey Epstein. She also wants a ...

Please provide your email address to receive an email when new articles are posted on . There were no serious bacterial infections or hospitalizations due to infection over 12 months among adults ...